Perhexiline potentiates the responsiveness of platelets to nitric oxide (NO) in patients with stable angina pectoris (SAP) and those with acute coronary syndromes (ACS), Australian cardiologists report.
Perhexiline is a prophylactic antianginal agent used frequently in Australia. Dr. John D. Horowitz and associates of the University of Adelaide report in the European Heart Journal for December that they had previously shown that platelets from patients with SAP and with ACS are less responsive to NO than platelets from patients without coronary disease.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!